Antithrombotic treatment of acute coronary syndrome consists of aspirin and (low-molecular weight) heparin, whereas oral glycoprotein IIb/IIIa receptor antagonists as a routine cannot be advised and thrombolytic therapy is not indicated at all. Long-term protection also consists of antiplatelet therapy and, if indicated, by anticoagulant therapy, given either as low-molecular weight heparin or as oral anticoagulants.